WSGR logoWSGR logo
Yang Liao
Associate
Corporate
Shanghai

D86-61651732

Download vCard
Open PDF

Yang Liao is an associate in the Shanghai office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on mergers and acquisitions and capital market transactions.

Before joining the firm, Yang practiced as an associate for Fandga Partners and served as legal counsel for Lilly Asia Ventures. She has represented clients in various industries including life sciences, semiconductors, technology, media, and telecom (TMT), and logistics with a business focus in the China market.

Experience

Yang Liao is an associate in the Shanghai office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on mergers and acquisitions and capital market transactions.

Before joining the firm, Yang practiced as an associate for Fandga Partners and served as legal counsel for Lilly Asia Ventures. She has represented clients in various industries including life sciences, semiconductors, technology, media, and telecom (TMT), and logistics with a business focus in the China market.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Boyu Capital on $110 Million Convertible Bond Investment in Gushengtang
On January 26, 2026, Gushengtang Holdings Limited (Gushengtang) announced that it had entered into a subscription agreement with an investment vehicle of Boyu Capital for the issuance and subscription of convertible bonds of Gushengtang in the aggregate principal amount of $110 million.
Learn More
Client Highlights
Wilson Sonsini Advises WuXi AppTec on Sale of China-Based Clinical Research Services Business to Hillhouse
On October 24, 2025, WuXi AppTec Co., Ltd. (WuXi AppTec), a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that its wholly owned subsidiary has entered into a sale and purchase agreement to sell its two subsidiaries, WuXi Clinical Development Services (Shanghai) Co., Ltd. (WuXi Clinical) and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. (WuXi MedKey), to Hillhouse Investment Management (Hillhouse), one of the world’s leading global private asset managers focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology. WuXi Clinical and WuXi MedKey are the operating entities of WuXi AppTec engaged in China-based clinical research services.

Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction. The Wilson Sonsini team includes:
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.